AUPP345098A0 - Novel anti-fibrinolytic agents - Google Patents

Novel anti-fibrinolytic agents

Info

Publication number
AUPP345098A0
AUPP345098A0 AUPP3450A AUPP345098A AUPP345098A0 AU PP345098 A0 AUPP345098 A0 AU PP345098A0 AU PP3450 A AUPP3450 A AU PP3450A AU PP345098 A AUPP345098 A AU PP345098A AU PP345098 A0 AUPP345098 A0 AU PP345098A0
Authority
AU
Australia
Prior art keywords
inhibitors
novel anti
plasmin
fibrinolytic agents
textilis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPP3450A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
National Institute for Biological Standards and Control
Original Assignee
NAT INST OF BIOLOG STANDARDS A
University of Queensland UQ
National Institute for Biological Standards and Control
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NAT INST OF BIOLOG STANDARDS A, University of Queensland UQ, National Institute for Biological Standards and Control filed Critical NAT INST OF BIOLOG STANDARDS A
Priority to AUPP3450A priority Critical patent/AUPP345098A0/en
Publication of AUPP345098A0 publication Critical patent/AUPP345098A0/en
Priority to NZ508770A priority patent/NZ508770A/en
Priority to JP2000548371A priority patent/JP4542705B2/ja
Priority to ES99918966T priority patent/ES2332249T3/es
Priority to AU36922/99A priority patent/AU759190B2/en
Priority to DE69941292T priority patent/DE69941292D1/de
Priority to PCT/AU1999/000343 priority patent/WO1999058569A1/en
Priority to AT99918966T priority patent/ATE440108T1/de
Priority to US09/700,179 priority patent/US7070969B1/en
Priority to DK99918966T priority patent/DK1078003T3/da
Priority to CA2328431A priority patent/CA2328431C/en
Priority to EP99918966A priority patent/EP1078003B1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AUPP3450A 1998-05-11 1998-05-11 Novel anti-fibrinolytic agents Abandoned AUPP345098A0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
AUPP3450A AUPP345098A0 (en) 1998-05-11 1998-05-11 Novel anti-fibrinolytic agents
EP99918966A EP1078003B1 (en) 1998-05-11 1999-05-07 Plasmin inhibitors from the australian brown snake, pseudonaja textilis textilis
AU36922/99A AU759190B2 (en) 1998-05-11 1999-05-07 Plasmin inhibitors from the Australian brown snake (Pseudonaja textilis textilis)
JP2000548371A JP4542705B2 (ja) 1998-05-11 1999-05-07 オーストラリア・ブラウン・スネーク，プソイドナジャ・テキスティリス・テキスティリスからのプラスミンインヒビター
ES99918966T ES2332249T3 (es) 1998-05-11 1999-05-07 Inhibidores de plasmina de la serpiente marron australiana, pseudonaja textilis textilis.
NZ508770A NZ508770A (en) 1998-05-11 1999-05-07 Textilinin plasmin inhibitors from the Australian brown snake pseudonaja textilis textilis
DE69941292T DE69941292D1 (de) 1998-05-11 1999-05-07 Schlange, pseudonaja textilis textilis
PCT/AU1999/000343 WO1999058569A1 (en) 1998-05-11 1999-05-07 PLASMIN INHIBITORS FROM THE AUSTRALIAN BROWN SNAKE $i(PSEUDONAJA TEXTILIS TEXTILIS)
AT99918966T ATE440108T1 (de) 1998-05-11 1999-05-07 Plasmin-inhibitoren von der australischen braunen schlange, pseudonaja textilis textilis
US09/700,179 US7070969B1 (en) 1998-05-11 1999-05-07 Plasmin inhibitors from the australian brown snake Pseudonaja textilis textilis
DK99918966T DK1078003T3 (da) 1998-05-11 1999-05-07 Plasmin-inhibitorer fra den australske brune slange, pseudonaja textilis textilis
CA2328431A CA2328431C (en) 1998-05-11 1999-05-07 Plasmin inhibitors from the australian brown snake pseudonaja textilis textilis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPP3450A AUPP345098A0 (en) 1998-05-11 1998-05-11 Novel anti-fibrinolytic agents

Publications (1)

Publication Number Publication Date
AUPP345098A0 true AUPP345098A0 (en) 1998-06-04

Family

ID=3807704

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPP3450A Abandoned AUPP345098A0 (en) 1998-05-11 1998-05-11 Novel anti-fibrinolytic agents

Country Status (11)

Country Link
US (1) US7070969B1 (https=)
EP (1) EP1078003B1 (https=)
JP (1) JP4542705B2 (https=)
AT (1) ATE440108T1 (https=)
AU (1) AUPP345098A0 (https=)
CA (1) CA2328431C (https=)
DE (1) DE69941292D1 (https=)
DK (1) DK1078003T3 (https=)
ES (1) ES2332249T3 (https=)
NZ (1) NZ508770A (https=)
WO (1) WO1999058569A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP345098A0 (en) * 1998-05-11 1998-06-04 National Institute Of Biological Standards And Control, United Kingdom Novel anti-fibrinolytic agents
US6506365B1 (en) * 2000-09-25 2003-01-14 Baxter Aktiengesellschaft Fibrin/fibrinogen binding conjugate
US7745192B2 (en) 2002-04-03 2010-06-29 Venomics Pty Limited Prothrombin activating protein
ES2431526T3 (es) 2005-12-29 2013-11-26 The Regents Of The University Of California Office Of Technology Transfer Procedimientos y composiciones relacionadas con el dominio Kunitz I mutante de TFPI-2
EP2154152A1 (en) * 2008-08-08 2010-02-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of Conkunitzin-S1 for the modulation of glucose-induced insulin secretion
US20110287036A1 (en) * 2008-11-17 2011-11-24 Riken Novel cancer targeting therapy using complex of subtance capable of binding specifically to constituent factor of cancer stroma and anti-tumor compound
CN102850451B (zh) * 2011-06-29 2014-05-07 辽宁诺康生物制药有限责任公司 具有抑制纤溶酶活性的重组textilinin-1及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342830A (en) * 1990-11-16 1994-08-30 Cor Therapeutics, Inc. Antithrombosis agents
EP0585504A1 (en) * 1992-09-04 1994-03-09 Pentapharm A.G. Phospholipid dependant prothrombin activator and its use in lupus anticoagulant testing
AUPP076797A0 (en) * 1997-12-05 1998-01-08 Active (Pla) R&D Pty Ltd Phospholipase inhibitor
AUPP345098A0 (en) * 1998-05-11 1998-06-04 National Institute Of Biological Standards And Control, United Kingdom Novel anti-fibrinolytic agents

Also Published As

Publication number Publication date
ATE440108T1 (de) 2009-09-15
CA2328431A1 (en) 1999-11-18
DE69941292D1 (de) 2009-10-01
NZ508770A (en) 2003-12-19
EP1078003B1 (en) 2009-08-19
ES2332249T3 (es) 2010-01-29
EP1078003A1 (en) 2001-02-28
JP4542705B2 (ja) 2010-09-15
WO1999058569A1 (en) 1999-11-18
JP2002514404A (ja) 2002-05-21
CA2328431C (en) 2010-04-27
US7070969B1 (en) 2006-07-04
DK1078003T3 (da) 2009-12-07
EP1078003A4 (en) 2004-08-25

Similar Documents

Publication Publication Date Title
BG104780A (en) Inhibitors of phospholipase enzymes
DE69905476D1 (en) Phosphonsaürederivate als ptp-1b-inhibitoren
PL343904A1 (en) Compounds and methods for the inhibition of the expression of vcam-1
WO1999005096A3 (en) Urokinase inhibitors
WO2004006858A3 (en) Compounds, compositions, and methods employing same
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
AU3652102A (en) Compounds and their uses
WO2000066104A3 (en) Ace-2 inhibiting compounds and methods of use thereof
BR0013200A (pt) Compostos derivados de heterobiciclos contendo nitrogênio, composições farmacêuticas, método de tratamento ou prevenção de uma disfunção tromboembólica e uso dos compostos
MXPA05012812A (es) Compuestos, metodos y composiciones farmaceuticas para inhibir poli(adenosina-5'-difosfo-ribosa)polimerasa(parp).
AP2001002187A0 (en) Piperidines as CCR5 modulators.
WO2001035950A3 (en) Benzamide therapeutics and methods for treating inflammatory bowel disease
HRP20020330B1 (https=)
PL341047A1 (en) Novel compounds
MXPA03001536A (es) (aminoalcoxibenzoil) benzofuranos o benzotiofenos, metodo para preparar los mismo y composiciones que los contienen.
AUPP345098A0 (en) Novel anti-fibrinolytic agents
DE69715173D1 (en) Bisarylcyclobutenderivate als cyclooxygenasehemmer
WO2002041831A3 (en) Inositol derivatives for increasing chloride secretion and inhibiting inflammation
TR200200278T2 (tr) Kalsilitik bileşimler
IL139144A0 (en) Mycobacterial inhibitors
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
MXPA03001986A (es) Composiciones antitromboticas.
PT1276722E (pt) Inibidores de naftamidina-uroquinase
MXPA03010259A (es) Nuevos derivados de 5-tio-ss-d-xilopiranosida, procedimiento de preparacion, composiciones farmaceuticas que los contienen y el uso terapeutico de los mismos.
EP1436279A4 (en) CHEMICAL COMPOUNDS